A R T I C L E S
Eroy-Reveles et al.
delivering NO (NO donors) on demand.7 To date, a variety of
NO donors, both organic and metal-based, have been synthe-
sized. These exogenous NO sources release NO via enzymatic
pathways as well as by stimuli such as change in pH, heat, and
light.8 Among the organic NO donors, selected diazeniumdi-
olates (NONOates) and S-nitrosothiols (such as S-nitrosoglu-
tathione (GSNO) and S-nitroso-N-acetylpenicillamine SNAP)
have been shown to induce apoptosis in a variety of cell
types.9,10 NO donors that release NO photochemically have
generated much interest because they allow localized release
of NO and could be used for photodynamic therapy (PDT) of
cancer cells.11,12 It has been demonstrated that cells subjected
to PDT produce NO.13 Because NO reacts with various reactive
oxygen species generated by PDT, it has been suggested that
NO contributes to the effective outcome of PDT treatment.14
In recent years, interest in metal NO complexes (nitrosyls) has
been renewed following the successful use of sodium nitro-
prusside (Na2[Fe(CN)5NO], SNP) as a NO donor drug to control
blood pressure during hypertensive episodes.15 Interestingly,
nitrosyls like SNP and Roussin’s salts (iron-sulfur clusters that
store multiple equivalents of NO) release NO upon illumination
with light (300-500 nm).16,17 However, low quantum yields
(Φ) and problems associated with ancillary ligands (such as
cyanide in case of SNP) limit the use of such nitrosyls in PDT.18
We have recently focused our attention on designed metal
nitrosyls that rapidly release NO upon illumination with low-
intensity light of low frequency.19-29 In such attempts, we have
employed nonporphyrin polydentate ligands30 to avoid problems
associated with rapid NO recombination reactions (commonly
observed with metal nitrosyls derived from porphyrin ligands)31,32
and toxicity arising from ancillary ligands.17 Careful consider-
ation of several metric, spectroscopic, and redox parameters (as
discussed in our previous papers) led us to the designed ligand
PaPy3H (N,N-bis(2-pyridylmethyl)amine-N-ethyl-2-pyridine-2-
carboxamide). This pentadentate ligand allowed us to synthesize
the first non-heme diamagnetic {Fe-NO}6 nitrosyl33 [Fe-
(PaPy3)(NO)](ClO4)2 that rapidly releases NO upon illumination
with 5-10 mW of Visible light (500-600 nm) in solvents like
acetonitrile (Φ ) 0.18).19,20 Our results strongly suggest that
the presence of the deprotonated carboxamido nitrogen (a strong
σ-donating negatively charged donor) trans to the bound NO
in this nitrosyl is crucial for its photolability.21 Although [Fe-
(PaPy3)(NO)](ClO4)2 exhibits excellent NO photolability, its
stability in biological media is inadequate.22,23 To circumvent
this problem, we next synthesized the corresponding ruthenium
nitrosyl, namely, [Ru(PaPy3)(NO)](BF4)2.24 This nitrosyl is
soluble in water and very stable in aqueous solution (pH range
5-9), a prerequisite for biological use. Indeed, we have
employed this nitrosyl to deliver NO to biological targets such
as reduced myoglobin and cytochrome c oxidase.24,34 This
success, however, came with a compromise. [Ru(PaPy3)(NO)]-
(BF4)2 releases NO only when exposed to low-intensity UV light
(5-10 mW, 300-450 nm); no appreciable NO photolability is
observed with visible light. Although the intensity of UV light
required for NO photolability is very low for [Ru(PaPy3)(NO)]-
(BF4)2 compared to other UV-sensitive ruthenium nitrosyls,35,36
the need for an efficient NO donor that operates under visible
light remained open. The quest came to a decent stop when we
synthesized the manganese nitrosyl, [Mn(PaPy3)(NO)]ClO4
(1).28 This {Mn-NO}6 nitrosyl is stable in aqueous buffer and
rapidly releases NO when exposed to Visible light (500-650
nm), affording the Mn(II) aqua species [Mn(PaPy3)(H2O)]ClO4.
We have been able to employ 1 as a photosensitive NO donor
(6) (a) Simeone, A.-M.; Collela, S.; Krahe, R.; Johnson, M. M.; Mora, E.;
Tari, A. M. Carcinogenesis 2006, 27, 568-577. (b) Crowell, J. A.; Steele,
V. E.; Sigman, C. C.; Fay, J. R. Mol. Cancer Ther. 2003, 2, 815-823. (c)
Hobbs, A. J.; Higgs, A.; Moncada, S. Ann. ReV. Pharmacol. Toxicol. 1999,
39, 191-220. (d) Bru¨ne, B.; von Knethen, A.; Sandau, K. Eur. J.
Pharmacol. 1998, 351, 261-272.
(7) (a) Thatcher, G. R. J. Curr. Top. Med. Chem. 2005, 5, 597-601. (b) Napoli,
C.; Ignarro, L. J. Annu. ReV. Pharmacol. Toxicol. 2003, 43, 97-123. (c)
Feelish, M. Naunyn-Schmiedeberg’s Arch. Pharmacol. 1998, 358, 113-
122. (d) Keefer, L. K.; Nims, R. W.; Davies, K. M.; Wink, D. A. Methods
Enzymol. 1996, 268, 281-293.
(8) (a) Nitric Oxide Donors; Wang, P. G., Cai, T. B., Taniguchi, N., Eds.;
Wiley: Weinheim, Germany, 2005. (b) Wang, P. G.; Xian, M.; Tang, X.;
Wu, X.; Wen, Z.; Cai, T.; Janczuk, A. J. Chem. ReV. 2002, 102, 1091-
1134.
(20) Patra, A. K.; Rowland, J. M.; Marlin, D. S.; Bill, E.; Olmstead, M. M.;
Mascharak, P. K. Inorg. Chem. 2003, 42, 6812-6823.
(21) Patra, A. K.; Olmstead, M. M.; Mascharak, P. K. Inorg. Chem. 2002, 41,
5403-5409.
(9) (a) Keefer, L. K. Curr. Top. Med. Chem. 2005, 5, 625-636. (b) Keefer, L.
K. Annu. ReV. Pharmacol. Toxicol. 2003, 43, 585-607.
(10) (a) Jekabsone, A.; Dapkunas, Z.; Brown, G. C.; Borutaite, V. Biochem.
Pharmacol. 2003, 66, 1513-1519. (b) Callsen, D.; Bru¨ne, B. Biochemistry
1999, 38, 2279-2286.
(22) Afshar, R. K.; Patra, A. K.; Olmstead, M. M.; Mascharak, P. K. Inorg.
Chem. 2004, 43, 5736-5743.
(11) (a) Pavlos, C. M.; Xu, H.; Toscano, J. P. Curr. Top. Med. Chem. 2005, 5,
637-647. (b) Pavlos, C. M.; Xu, H.; Toscano, J. P. Free Radical Biol.
Med. 2004, 37, 745-752.
(23) Eroy-Reveles, A. A.; Hoffman-Luca, C. G.; Mascharak, P. K. Dalton Trans.
2007, 5268-5274.
(24) Patra, A. K.; Mascharak, P. K. Inorg. Chem. 2003, 42, 7363-7365.
(25) Patra, A. K.; Rose, M. J.; Murphy, K. A.; Olmstead, M. M.; Mascharak,
P. K. Inorg. Chem. 2004, 43, 4487-4495.
(12) Ford, P. C.; Bourassa, J.; Miranda, K.; Lee, B;, Lorkovic, I.; Boggs, S.;
Kudo, S.; Laverman, L. Coord. Chem. ReV. 1998, 171, 185-202.
(13) (a) Ali, S. M.; Olivo, M. Int. J. Oncol. 2003, 22, 751-756. (b) Gupta, S.;
Ahmad, N.; Mukhtar, H. Cancer Res. 1998, 58, 1785-1788.
(14) (a) Yamamoto, F.; Ohgari, Y.; Yamaki, N.; Kitajima, S.; Shimokawa, O.;
Matsui, H.; Taketani, S. Biochem. Biophys. Res. Commun. 2007, 353, 541-
546. (b) Lu, Z.; Tao, Y.; Zhou, Z.; Zhang, J.; Li, C.; Ou, L.; Zhao, B. Free
Radical Biol. Med. 2006, 41, 1590-160.
(26) Rose, M. J.; Patra, A. K.; Alcid, E. A.; Olmstead, M. M.; Mascharak, P.
K. Inorg. Chem. 2007, 46, 2328-2338.
(27) Rose, M. J.; Olmstead, M. M.; Mascharak, P. K. Polyhedron 2007, 26,
4713-4718.
(28) Ghosh, K.; Eroy-Reveles, A. A.; Avila, B.; Holman, T. R.; Olmstead, M.
M.; Mascharak, P. K. Inorg. Chem. 2004, 43, 2988-2997.
(29) Ghosh, K.; Eroy-Reveles, A. A.; Olmstead, M. M.; Mascharak, P. K. Inorg.
Chem. 2005, 44, 8469-8475.
(15) (a) Butler, A. R.; Megson, I. L. Chem. ReV. 2002, 102, 1155-1165. (b)
Matthews, E. K.; Seaton, E. D.; Forsyth, M. J.; Humphrey, P. P. A. Br. J.
Pharmacol. 1994, 113, 87-94. (c) Clarke, M. J.; Gaul, J. B. Struct. Bonding
(Berlin) 1993, 81, 147-181. (d) Arnold, W. P.; Longnecker, D. E.; Epstein,
R. M. Anesthesiology 1984, 61, 254-60. (e) Palmer, R. F.; Lasseter, K. C.
N. Engl. J. Med. 1975, 292, 294-297.
(16) Bourassa, J.; DeGraff, W.; Kudo, S.; Wink, D. A.; Mitchell, J. B.; Ford, P.
C. J. Am. Chem. Soc. 1997, 119, 2853-2860.
(17) Conrado, C. L.; Bourassa, J. L.; Egler, C.; Wecksler, S.; Ford, P. C. Inorg.
Chem. 2003, 42, 2288-2293.
(30) Rowland, J. M.; Olmstead, M. M.; Mascharak, P. K. Inorg. Chem. 2001,
40, 2810-2817.
(31) (a) Ford, P. C.; Laverman, L. E. Coord. Chem. ReV. 2005, 249, 391-403.
(b) Ford, P. C.; Fernandez, B. O.; Lim, M. D. Chem. ReV. 2005, 105, 2439.
(c) Hoshino, M.; Laverman, L.; Ford, P. C. Coord. Chem. ReV. 1999, 187,
75-102.
(32) Lim, M. D.; Lorkovic, I. M.; Ford, P. C. J. Inorg. Biochem. 2005, 99,
151-165.
(18) (a) Alaniz, C.; Watts, B. Ann. Pharmacother. 2005, 39, 388-389. (b)
Janczyk, A.; Wolnicka-Glubisz, A.; Chmura, A.; Elas, M.; Matuszak, Z.;
Stochel, G.; Urbanska, K. Nitric Oxide 2004, 10, 42-50. (c) Bourassa, J.;
Lee, B.; Bernard, S.; Schoonover, J.; Ford, P. C. Inorg. Chem. 1999, 38,
2947-2952. (d) Mayer, B.; Brunner, F.; Schmidt, K. Biochem. Pharmacol.
1993, 45, 367-374. (e) Robin, E. D.; McCauley, R. Chest 1992, 102,
1842-1845.
(33) The {M-NO}n notation used in this paper is that of Feltham and Enemark.
See Enemark, J. H.; Feltham, R. D. Coord. Chem. ReV. 1974, 13, 339-
406.
(34) Szundi, I.; Rose, M. J.; Sen, I.; Eroy-Reveles, A. A.; Mascharak, P. K.;
Einarsdottir, O. Photochem. Photobiol. 2006, 82, 1377-1384.
(35) Tfouni, E.; Krieger, M.; McGarvey, B. R.; Franco, D. W. Coord. Chem.
ReV. 2003, 236, 57-69.
(36) Serli, B.; Zangrando, E.; Gianferrara, T.; Yellowlees, L.; Alessio, E. Coord.
Chem. ReV. 2003, 245, 73-83.
(19) Patra, A. K.; Afshar, R. K.; Olmstead, M. M.; Mascharak, P. K. Angew.
Chem., Int. Ed. 2002, 41, 2512-2515.
9
4448 J. AM. CHEM. SOC. VOL. 130, NO. 13, 2008